Synthetic Immune Receptor, A Next Generation CAR-T Platform
Time: 3:00 pm
day: Post-Conference Solid Tumor Focus Day
Details:
- Describing the current challenges facing cell therapy
- Describing the reasons why CAR-T therapies have failed and especially in solid tumors
- Introducing Synthetic Immune Receptor (SIR), a next generation HLA-independent TCR platform and describing the activity of SIR against solid tumors and blood cancers
